Document:

Non-Exclusive Cabilly Patent License Agreement

[***] Confidential treatment requested 
 
 
Exhibit 10.2 
 
CONFIDENTIAL

 
NON-EXCLUSIVE CABILLY PATENT LICENSE
AGREEMENT 
 
[Cabilly Coexpression Patents]

 
This Non-Exclusive Cabilly Patent License
Agreement (“Agreement”) is effective as of March 6th 2003 (“Effective Date”) by
and between Genentech, Inc., a Delaware corporation having its principal place of business at 1 DNA Way, South San Francisco, California 94080 (hereinafter “Genentech”) and Seattle Genetics, Inc., a Delaware corporation having its
principal place of business at 21823 30th Drive S.E., Bothell, WA 98021 (hereinafter “Licensee”). 
 
WHEREAS: 
 

	A.	 	Genentech owns and controls certain patent rights relating to methods and compositions in the field of antibodies (the “Licensed Patents”, as that
term is defined below); 

 

	B.	 	Licensee is developing, and intends to commercialize, antibody products that bind to the CD40 antigen (“CD40”) and wishes to acquire a non-exclusive
license for such products under the Licensed Patents; and 

 

	C.	 	Genentech is willing to grant such a non-exclusive license to Licensee on the terms and conditions set forth below. 

 
NOW, THEREFORE, in consideration of the promises and the mutual covenants
recited herein, the Parties agree as follows: 
 

1 

[***] Confidential treatment requested 
 
 
Article I 
 
DEFINITIONS

 
Unless otherwise specifically set forth herein,
the following terms shall have the following meanings: 
 
1.01. “Affiliate” with respect to Licensee shall mean any corporation or other entity which, directly or indirectly, controls, is controlled by or is under common control with, a Party. For the purpose of this Section 1.01
“control” shall mean (i) the ownership, directly or indirectly, of at least fifty percent (50%) of the outstanding voting securities or other ownership interest of an entity, or (ii) the possession, directly or indirectly, of the
power to manage, direct or cause the direction of the management and policies of the corporation or other entity or the power to elect or appoint fifty percent (50%) or more of the members of the governing body of the corporation or other entity.

 
1.02. “Bulk Product” shall mean
Licensed Product supplied in a form other than Finished Product which can be converted into Finished Product. 
 
1.03. “Calendar Quarter” shall mean each three month period commencing January 1, April 1, July 1 and October 1 of each year
during the term of this Agreement. 
 
1.04.
“Chimera Patents” shall mean (i) U.S. Patent No. 4,816,567, issued March 28, 1989 from U.S. patent application serial no. (USSN) 06/483,457, and (ii) any claims directed to chimeric antibodies or any method of making or using chimeric
antibodies, which claims are found in any patent(s) issuing from divisionals, continuations, or continuations-in-part of any application from which U.S. Patent No. 4,816,567 claims priority, (iii) any claims directed to chimeric antibodies or any
method of making or using chimeric antibodies, which claims are found in any patents that are reissues, reexaminations, or extensions of any of the foregoing (i) and (ii), and (iv) foreign counterparts of any of the foregoing (i), (ii), or (iii).

 

2 

[***] Confidential treatment requested 
 
 
1.05. “Cost of Product” shall mean the cost of acquisition, if purchased, or the cost of manufacture, the latter being the sum of direct production costs and manufacturing overhead costs determined in accordance with U.S.
Generally Accepted Accounting Principles (“GAAP”). 
 
1.06. “Designee” shall mean a corporation or other entity designated by Licensee to exercise the rights of Licensee hereunder in concert with, or in place of and to the exclusion of, Licensee in all or any part of
the Territory. 
 
1.07. “Field of Use”
shall mean any human use. 
 
1.08. “Finished
Product” shall mean any and all Licensed Product in a form for use by an end user and not intended for further chemical or genetic manipulation or transformation. 
 
1.09 “First Commercial Sale” shall mean the first sale of any Licensed Product by Licensee or any
of its Affiliates or Designees to a non-affiliated third party. The sale shall be deemed to occur on the earlier of (i) the date the Licensed Product is shipped to the third party, or (ii) the date of the invoice to the third party for the Licensed
Product. 
 
1.10. “Licensed Patents”
shall mean (i) U.S. Patent No. 6,331,415, issued December 18, 2001, (ii) any patent(s) issuing from divisionals, continuations, or continuations-in-part of any patent application from which U.S. Patent No. 6,331,415 claims priority, and (iii)
patents that are reissues, reexaminations, extensions, or foreign counterparts of any of the foregoing (i) or (ii), provided, however, that Licensed Patents shall not include Chimera Patents. 
 
1.11. “Licensed Product” shall mean any antibody
that binds specifically to CD40, the making (or having made), using, selling, offering for sale or importing of which, but for the license granted under this Agreement, would infringe a Valid Claim of a patent included in Licensed Patents.

 

3 

[***] Confidential treatment requested 
 
 
1.12. “Net Sales” shall mean the gross invoice or contract price to third party customers for Finished Product. Finished Product used or consumed by Licensee or its Affiliates or Designees as part of the delivery of
services to customers for which Licensee derives compensation shall be considered Net Sales at the gross invoice or contract price of like Finished Product which are sold to customers. If Licensed Product is sold in combination with one or more
active ingredients, Net Sales shall be calculated by multiplying Net Sales of the combination product by the fraction A/(A+B) where A is the sales price of the Finished Product in the combination when sold separately and B is the total sales price
of all other active ingredients in the combination when sold separately. If the Finished Product and the other active ingredients are not sold separately, the percentage of the total cost of the combination product attributed to Cost of Product
shall be multiplied times the sales price of the combination product to arrive at Net Sales. For all Licensed Product used or consumed by others than Licensee, Licensee shall be entitled to deduct [***] from Net Sales in lieu of all other deductions
such as taxes, shipping charges, allowances and the like prior to calculating royalties due. 
 
Net Sales for Bulk Products shall be calculated by doubling the gross invoice or contract price of Bulk Products sold to non-affiliated customers. 
 
The method of calculating Net Sales of materials in form other
than Finished Product or Bulk Product that can be converted into Finished Product shall be established by the Parties prior to the first sale or transfer of any such material by Licensee, its Affiliates or Designees to a non-affiliated third party.

 
1.13. “Party” shall mean either
Genentech or Licensee, and when used in the plural shall mean both Genentech and Licensee. 
 
1.14 “SGI Licensed Product” shall mean a Licensed Product the research and/or development of which was materially conducted by Licensee. 
 
1.15. “Term” is defined in Section 7.01.

 
1.16. “Territory” shall mean the
entire world. 
 

4 

[***] Confidential treatment requested 
 
 
1.17. “U.S.” and “United States” shall mean the United States of America, including its territories and possessions. 
 
1.18. “Valid Claim” shall mean any claim of an issued and unexpired patent within the Licensed Patents that has not been
disclaimed, abandoned or dedicated to the public or held unenforceable, unpatentable or invalid by a decision of a court or governmental agency of competent jurisdiction, which decision is unappealable or unappealed within the time allowed for
appeal. 
 
Article II 
 
GRANT 
 
2.01. License. Genentech hereby grants to Licensee and
Licensee hereby accepts a non-exclusive license under Licensed Patents during the Term to research, develop, make (and have made), use, sell, offer for sale, export and import Licensed Product in the Territory in the Field of Use. The license
granted under this Section 2.01 shall be non-sublicensable, except that Licensee shall have a limited right to grant sublicenses as provided in Section 2.02. 
 
2.02. Right to Grant Sublicenses. Licensee shall [***] have the right to grant sublicenses [***] (a “Sublicensee”)
of the rights granted under Section 2.01 to research, develop, make (and have made), use, sell, offer for sale, export and import SGI Licensed Product, in all or any part of the Territory; provided that Licensee shall always be responsible for the
payment of royalties on Net Sales of SGI Licensed Product by any such Sublicensee and for all other acts of such Sublicensee as if such acts were those of the Licensee. Any sublicenses granted hereunder shall not be further sublicensable or
sublicensed by a Sublicensee thereof except [***]. Furthermore, any such sublicense shall include a provision that such Sublicensee is bound to at least the same limitations and restrictions as the limitations and restrictions of this Agreement on
Licensee, including, without limitation, a provision granting to Licensee audit rights similar to Genentech’s audit rights under Section 4.01 of this Agreement, which rights Licensee agrees to exercise for Genentech at Genentech’s request
and expense. Licensee shall notify Genentech in writing 
 

5 

[***] Confidential treatment requested 
 
promptly after the grant of any such sublicense including in such notice the
name and address of the Sublicensee and the identity of the SGI Licensed Product(s) and field(s) that are covered by the sublicense. 
 
2.03. No Other License. Licensee understands and agrees that no license under any patent or patent application other than Licensed
Patents, or under any know-how, is or shall be deemed to have been granted under this Agreement, either expressly or by implication. By way of example only, and without limitation, no license under Chimera Patents is granted hereunder. 
 
Article III 
 
FEES, MILESTONES AND ROYALTIES 
 
3.01. License Grant Fee. Licensee shall pay to
Genentech a non-creditable, non-refundable license grant fee of [***] dollars (U.S. $[***]) in [***]. Within [***] ([***]) [***] after the Effective Date, Licensee shall make the [***] of U.S. $[***]. In addition, within [***] ([***]) [***] after
the [***] of the Effective Date, Licensee shall make the [***] of U.S. $[***]. 
 
3.02. Development Milestone Fee. Within [***] ([***]) [***] after [***], Licensee shall pay to Genentech a non-creditable, non-refundable development milestone fee of [***] dollars (U.S.
$[***]). 
 
3.03. Earned Royalties. Licensee
shall pay to Genentech a royalty of [***] percent ([***]%) of Net Sales of all Licensed Product. 
 
3.04. Sales To or Between Licensee, Affiliates, and Designees. It is the intent of the Parties that Net Sales shall be based on arm’s length sales transactions to non-affiliated third
parties. No royalties shall be paid upon sales of Licensed Product to or between any of Licensee, its Affiliates and Designees for further sale; provided, however, that in such cases royalties shall be paid upon such further sale of Licensed Product
by Licensee, its Affiliates or Designees to non-affiliated third parties. 
 

6 

[***] Confidential treatment requested 
 
 
3.05. No Non-Monetary Consideration. Without the prior written consent of Genentech, Licensee, its Affiliates and Designees shall not solicit or accept any consideration for the sale of any Licensed Product other than as will
be accurately reflected in Net Sales. 
 
3.06.
No Credit Against Royalties. Licensee shall not be entitled to deduct any portion of royalties paid to any third party from the royalties due to Genentech pursuant to this Agreement for any reason. 
 
Article IV 
 
RECORDS, REPORTS AND PAYMENTS 
 
4.01. Records Retention. Licensee shall keep and shall
cause its Affiliates and Designees to keep true, complete and accurate records of all sales of all Licensed Product in accordance with GAAP, or the equivalent, and in sufficient detail to permit Genentech to confirm the accuracy of Licensee’s
royalty calculations. At Genentech’s request and expense, Licensee shall permit not more than once in a [***] ([***]) [***] period an independent certified public accountant appointed by Genentech and acceptable to Licensee to examine at
Licensee’s principal place of business, upon reasonable notice and at reasonable times, such records solely to the extent necessary to verify Licensee’s calculations. Licensee shall be responsible for providing access to such records that
in the ordinary course of business are in the possession or control of its Affiliates and Designees. Such examination shall be limited to a period of time no more than [***] ([***]) [***] immediately preceding the request for examination. The report
of any such examination shall be made simultaneously to Genentech and Licensee and shall simply report the amount, if any, by which Licensee has overpaid or underpaid its royalties. If Licensee’s royalties are found to be in error such that
royalties to Genentech were underpaid, then Licensee shall promptly pay the deficiency plus interest pursuant to Section 4.05 to Genentech; and if royalties to Genentech were underpaid by more than [***] percent ([***]%), then Licensee shall
additionally reimburse Genentech for its reasonable costs incurred in examining such records. 
 

7 

[***] Confidential treatment requested 
 
 
4.02. Reports. Within [***] ([***]) [***] after the end of each Calendar Quarter following the First Commercial Sale of Licensed Product, Licensee shall furnish to Genentech a written report of all sales of all Licensed
Product subject to royalty under Article III during such Calendar Quarter. Such report shall include, without limitation, (i) the determination of Net Sales as specified in Section 1.12, setting forth the amount of gross receipts, Net Sales, and any
deduction taken from gross receipts to arrive at Net Sales, for each of Finished Product and Bulk Product separately; and (ii) the royalty payment then due. Concurrently with each report pursuant to this Section 4.02, Licensee shall make the royalty
payment then due. 
 
4.03. Payments.
Payments shall be in United States dollars and, unless otherwise agreed in writing, shall be made by wire transfer of immediately available funds to such account of Genentech in such bank as Genentech may from time to time designate in writing. All
royalty payments shall be free and clear of any taxes, duties, levies, fees or charges, except for withholding taxes. Licensee shall pay any withholding tax due on behalf Genentech and such withholding taxes shall be deducted from all payments due
hereunder. The Parties shall cooperate to take advantage of the benefit of any double taxation treaty(ies) that may be applicable. 
 
4.04. Currency Conversion. Royalties due on Net Sales of Licensed Product made in currency other than U.S. dollars shall be
expressed in the currency of the invoice issued in connection with the sale of such Licensed Product together with the U.S. dollar equivalent of the royalty due, calculated using the average rate of exchange published in Reuters during the
applicable Calendar Quarter. 
 
4.05.
Interest. All royalty payments not made when due shall bear interest, calculated from the date such payment was due, at the annual rate of [***] percent ([***]%) over the [***] as reported in the [***] on the day the payment was due.

 

8 

[***] Confidential treatment requested 
 
 
Article V 
 
REPRESENTATIONS,
WARRANTIES, AND DISCLAIMERS 
 
5.01. Genentech
represents and warrants that it has the right to grant the license granted under this Agreement. 
 
5.02. Nothing in this Agreement is or shall be construed as: 
 

	 	(i)	 	A warranty or representation by Genentech as to the validity or scope of any claim or patent or patent application within the Licensed Patents;

 

	 	(ii)	 	A warranty or representation by Genentech that anything made, used, sold, or otherwise disposed of under any license granted in this Agreement is or will be free
from infringement of any patent rights or other intellectual property right of any third party; 

 

	 	(iii)	 	A grant by Genentech, whether by implication, estoppel, or otherwise, of any licenses or rights other than that expressly granted under Section 2.01; or

 

	 	(iv)	 	An obligation to bring or prosecute actions or suits against any third party for infringement of any of the Licensed Patents. 

 
5.03. NO WARRANTY IS GIVEN WITH RESPECT TO THE LICENSED
PATENTS, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE, AND THE PARTIES SPECIFICALLY DISCLAIM ANY EXPRESS OR IMPLIED WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, VALIDITY OF THE LICENSED
PATENTS, OR NON-INFRINGEMENT OF THE PATENT OR OTHER RIGHTS OF ANY THIRD PARTY. 
 

9 

[***] Confidential treatment requested 
 
 
Article VI 
 
LIABILITY

 
6.01. Indemnification. Licensee shall
indemnify, defend and hold Genentech and its directors, officers, employees and agents harmless from and against any and all liabilities, claims, demands, expenses (including, without limitation, attorneys and professional fees and other costs of
litigation), losses or causes of action (each, a “Liability”) arising out of or relating in any way to (i) the possession, manufacture, use, sale or other disposition of Licensed Product hereunder, whether based on breach of
warranty, negligence, product liability or otherwise, (ii) the exercise of any right granted to Licensee pursuant to this Agreement, or (iii) any breach of this Agreement by Licensee, except to the extent, in each case, that such Liability is caused
by the negligence or willful misconduct of Genentech as determined by a court of competent jurisdiction; provided, however, that upon receiving notice of any such Liability, Genentech shall promptly notify Licensee and permit Licensee to handle and
control the defense (including litigation and settlement) of such Liability, at Licensee’s sole expense, and Genentech shall reasonably cooperate with the indemnifying Party in the defense of such Liability, at Licensee’s sole expense.

 
Article VII 
 
TERM AND TERMINATION 
 
7.01. Term. The term of this Agreement will commence on
the Effective Date and remain in full force and effect until the expiration of the last patent within the Licensed Patents (the “Term”), unless earlier terminated in accordance with this Article VII. 
 
7.02 Termination without Breach. Licensee shall have
the right to terminate this Agreement upon [***] ([***]) [***] prior written notice to Genentech. 
 
7.03. Termination for Breach. Genentech shall have the right to terminate this Agreement and the licenses granted hereunder upon
written notice to Licensee for a material breach of this Agreement if Licensee has failed to cure such breach within [***] ([***]) [***] 
 

10 

[***] Confidential treatment requested 
 
following notice thereof. Licensee’s failure to pay royalties and provide
reports to Genentech under this Agreement when due shall constitute a material breach. 
 
7.04. Insolvency. Genentech may terminate this Agreement if, at any time, Licensee shall file in any court pursuant to any statute of any individual state or country, a petition in bankruptcy,
insolvency or for reorganization or for an agreement among creditors or for the appointment of a receiver or trustee of Licensee or of its assets, or if Licensee proposes a written agreement of composition or extension of its debts, or if Licensee
shall be served with an involuntary petition against it filed in any insolvency proceeding, and such petition shall not be dismissed within [***] ([***]) [***] after the filing thereof, or if Licensee shall propose or be a party to any dissolution
or liquidation, or if Licensee shall make an assignment for the benefit of creditors. Any termination pursuant to this Section 7.04 shall be effective immediately upon notice of such termination. 
 
7.05. Effect of Termination. Termination of this
Agreement in whole or in part for any reason shall not relieve Licensee of its obligations to pay all fees and royalties that shall have accrued hereunder prior to the effective date of termination. Termination of this Agreement by or as to Licensee
shall result in the termination of the licenses granted to Licensee; provided, however, that a valid sublicense granted by Licensee to a Sublicensee under this Agreement shall survive termination of this Agreement and shall be deemed to be a direct
license from Genentech to Sublicensee, provided that (i) such Sublicensee is then in full compliance with all terms of this Agreement and the respective sublicense, (ii) such Sublicensee agrees in writing to assume all of the obligations of Licensee
under this Agreement and can reasonably show the capacity to comply with such obligations to the same extent as if such Sublicensee were an original party hereto, (iii) the obligations of Genentech under such direct license shall not be greater than
the obligations of Genentech under this Agreement, and (iv) the scope of such direct license shall not be broader than the rights sublicensed by Licensee to such Sublicensee. The provisions of Article IV, Article V, Article VI, Article VIII and this
Section 7.05 shall survive termination of the Agreement for any reason. 
 

11 

[***] Confidential treatment requested 
 
 
Article VIII 
 
MISCELLANEOUS
PROVISIONS 
 
8.01. Relationship of the
Parties. Nothing in this Agreement is intended or shall be deemed to constitute or give rise to a partnership, agency, distributorship, employer-employee, joint venture, or fiduciary relationship between the Parties. No Party shall incur any
debts or make any commitments for the other. 
 
8.02. Patent Prosecution, Maintenance and Enforcement. Genentech shall be solely responsible, at its sole discretion and expense, for the prosecution, defense, and maintenance of Licensed Patents, and for enforcing Licensed
Patents against actual or suspected third party infringers. 
 
8.03. Assignment. Neither Party shall assign any of its rights or obligations hereunder except: (i) as incident to the merger, consolidation, reorganization or acquisition of stock or assets affecting substantially all of the
assets or voting control of the assigning Party; (ii) to any corporation or other entity to which it may transfer substantially all of its assets related to the Licensed Product; (iii) to any wholly owned subsidiary if the assigning Party remains
liable and responsible for the performance and observance of all of the subsidiary’s duties and obligations hereunder; or (iv) with the prior written consent of the other Party (which consent shall not be unreasonably withheld); provided
however, that assignment in the context of insolvency or bankruptcy of Licensee shall require prior written consent of Genentech. This Agreement shall be binding upon the successors and permitted assigns of the Parties, and the name of a Party
appearing herein shall be deemed to include the names of such Party’s successor’s and permitted assigns to the extent necessary to carry out the intent of this Agreement. Any assignment not in accordance with this Section 8.03 shall be
void. 
 
8.04. Further Acts and Instruments.
Upon request by either Party, the other Party agrees to execute, acknowledge and deliver such further instruments, and to do all such other acts, as may be reasonably necessary or appropriate in order to carry out the purposes and intent of this
Agreement. 
 

12 

[***] Confidential treatment requested 
 
 
8.05. Trade Names and Trademarks. Except as otherwise provided herein, no right, expressed or implied, is granted by this Agreement to use in any manner the name “Genentech” or any other trade name or trademark of
Genentech in connection with the performance of this Agreement. Except as otherwise provided herein, no right, expressed or implied, is granted by this Agreement to use in any manner the name “Seattle Genetics” or any other trade name or
trademark of Licensee in connection with the performance of this Agreement. 
 
8.06. Entire Agreement. This Agreement constitutes and contains the entire understanding and agreement of the Parties with respect to the subject matter hereof, and cancels and supersedes any
and all prior negotiations, correspondence, understandings and agreements, whether verbal or written, between the Parties respecting the subject matter hereof. No waiver, modification, or amendment of any provision of this Agreement shall be valid
or effective unless made in writing and signed by a duly authorized representative of each of the Parties. 
 
8.07. Severability. In the event any one or more of the provisions of this Agreement should for any reason be held by any court or
authority having jurisdiction over this Agreement or either of the Parties to be invalid, illegal or unenforceable, such provision or provisions shall be validly reformed to as nearly as possible approximate the intent of the Parties and, if
unreformable, shall be divisible and deleted in such jurisdiction; elsewhere, this Agreement shall not be affected so long as the Parties are still able to realize the principal benefits bargained for in this Agreement. 
 
8.08. Waiver. The waiver by a Party of any breach of or
default under any of the provisions of this Agreement or the failure of a Party to enforce any of the provisions of this Agreement or to exercise any right hereunder shall not constitute or be construed as a waiver of any other breach or default or
as a waiver of any such rights or provisions hereunder. 
 
8.09. Choice of Law. This Agreement shall be governed by and interpreted in accordance with the laws of the State of California without regard to conflict of laws provisions. This Agreement shall be construed as if drafted
equally by the Parties, and in construing this 
 

13 

[***] Confidential treatment requested 
 
Agreement no presumption shall operate in either Party’s favor as a
result of the role of it or its counsel in drafting or negotiating the terms or provisions hereof. 
 
8.10. Notices. Any notice, request, consent, or other document required or permitted to be given under this Agreement or otherwise
relating to this Agreement shall be in writing and shall be deemed to have been sufficiently given if delivered in person, transmitted by facsimile (with a confirming copy sent by overnight courier), or sent by overnight courier or registered mail
to the Party to whom it is directed at its address shown below or such other address as such Party shall have last given by notice to the other Party. Any such notice, requests, delivery, approval or consent shall be deemed received on the date of
hand delivery or transmission by facsimile (provided that such date is a business day, otherwise it shall be deemed received on the next business day), one (1) business day after dispatch by overnight courier, or five (5) business days after
dispatch of the registered mail. 
 
If to
Licensee, addressed to: 
 
Seattle Genetics,
Inc. 
21823 30th Drive S.E. 
Bothell, WA 98021 
Attn: General Counsel 
 
Facsimile: (425) 527-4001 
 
If to Genentech, addressed to: 
 
Genentech, Inc. 
1 DNA Way 
South San Francisco, CA 94080 
Attn: Corporate Secretary 
 
Facsimile: (650) 952-9881 
 

14 

[***] Confidential treatment requested 
 
 
8.11. Confidentiality. Each Party shall be free to disclose the existence of this Agreement (but not its terms) to any third party. Neither Party shall disclose any of the terms (including, but not limited to, the financial
terms) of this Agreement to any third party without the prior written consent of the other Party; provided, however, that each Party shall be free to disclose any of the terms of this Agreement (i) to the extent that a Party reasonably believes it
is required to do so by securities or other applicable laws, regulations, or rules (including the regulations or rules of any relevant stock exchange), (ii) pursuant to a legal proceeding or order of a court or governmental agency, (iii) to actual
or prospective sublicensees, (iv) to [***], (v) to its accountants, attorneys and other professional advisors, or (vi) in connection with a financing, merger, consolidation, acquisition or a permitted assignment of this Agreement, provided that in
the case of any disclosure under (iii), (iv), (v), or (vi) above, the recipient(s) are obligated and do so undertake to keep such terms of this Agreement confidential to the same extent as said Party, and provided that in the case of disclosure
under (ii), the disclosing Party will use reasonable efforts to secure confidential treatment of such terms of this Agreement required to be disclosed. 
 
8.12. Counterparts. This Agreement may be executed simultaneously in one or more counterparts, each of which shall be deemed an
original, but all of which together shall constitute one and the same instrument. 
 
[Signature page follows] 
 

15 

[***] Confidential treatment requested 
 
 
IN WITNESS WHEREOF, Genentech and Licensee have caused this Agreement to be executed by their duly authorized representatives. 
 

	 GENENTECH, INC.

	
	 By:
	 	 /s/ Joseph S. McCracken

	 Joseph S. McCracken, D.V.M.
 Title: Vice President, Business and Commercial Development

 
Date: March 6th, 2003 
 

	 SEATTLE GENETICS, INC.

	
	 By:
	 	 /s/ Clay B. Siegall

	 Clay B. Siegall, Ph.D.
 Title: President and Chief Executive Officer                          
    

 
Date: March 18, 2003 
 

16HEI Executive Incentive Compensation Plan

 
HEI Exhibit
10.1 
 
HAWAIIAN ELECTRIC INDUSTRIES, INC.

EXECUTIVE INCENTIVE COMPENSATION PLAN (EICP) 
 
Pursuant to Section 3.1 of the 1987 Stock Option and Incentive Plan of Hawaiian Electric Industries, Inc. (as amended
and restated effective January 21, 2003), the Compensation Committee of the Board of Directors of Hawaiian Electric Industries, Inc. (HEI) establishes and adopts the following Executive Incentive Compensation Plan (EICP). 
 

	1.	 	PURPOSE 

 
The purpose of the EICP is to encourage a high level of performance by HEI and its subsidiaries (the “Company”) through the
establishment of specific financial and/or nonfinancial goals, the accomplishment of which will require a high degree of competence and diligence on the part of certain key employees of the Company selected to participate in the EICP, and will be
beneficial to the owners and customers of the Company. 
 

	2.	 	DEFINITIONS 

 
The following definitions apply to the EICP: 
 

	 	2.1	 	“Award” means payment made in accordance with the provisions of the EICP. 

 

	 	2.2	 	“Board of Directors” means the Board of Directors of HEI. 

 

	 	2.3	 	“Committee” means the Compensation Committee of the Board of Directors of HEI. 

 

	 	2.4	 	“Deferred Account” means an unfunded account within which a Participant’s deferred Awards and accrued interest are accumulated.

 

	 	2.5	 	“Executives” means the senior officers and managers responsible for determining business and strategic policies. 

 

	 	2.6	 	“Participant” means an employee selected to participate in the EICP. 

 

	 	2.7	 	“Performance Goals” means the performance objectives of the Company established for the purpose of determining any incentive Award for a Plan Year.

 

	 	2.8	 	“Plan Year” means the calendar year. 

 

	3.	 	BASIC PLAN CONCEPT 

 
The EICP provides an opportunity for Participants to earn annual incentive compensation Awards depending on the level of Company and
individual performance. Performance will be based on a twelve-month period beginning January 1 and ending December 31. Awards may be in cash or HEI Common Stock at the option of the Committee. Awards to Participants are based primarily on Company
Performance Goals and may be partially based on other factors including individual Performance Goals. Minimum financial performance “hurdles” will be established that must be exceeded before any Award is made. Unless otherwise specified,
the minimum performance hurdle for each individual will be the minimum of the performance target range for the earnings per share or Company income goal listed. When Awards are granted, payments will be made in cash and/or HEI Common Stock at the
sole discretion of the Committee, and such payments will be made shortly after the end of each Plan Year unless voluntarily deferred by the Participant. HEI Common Stock awards are subject to the availability of authorized shares. 
 

	4.	 	 ADMINISTRATION 

 
The EICP will be administered by the Committee which shall determine: 
 

	 	4.1	 	Participants; 

 

	 	4.2	 	Performance Goals; 

 

	 	4.3	 	Incentive Award levels; 

 

	 	4.4	 	Performance Goal results; and 

 

	 	4.5	 	Amount of the actual Award, if any, to be made to each Participant and whether it should be granted in cash and/or HEI Common Stock. 

 

	5.	 	PARTICIPATION 

 
The Committee will select Participants form those executives whose decisions contribute directly to the annual success of the Company. No
employee will at any time have the automatic right to be selected as a Participant in the EICP for any Plan Year, nor, if so selected, to be entitled automatically to an Award, nor, having been selected as a Participant for one Plan Year, to be
automatically selected as a Participant in any subsequent Plan Year. 
 
Participants may be placed in the plan after the start of the Plan Year; provided that any awards will be pro-rated based on the percentage of time the Participant was in the plan. If a Participant terminates employment
before the end of the Plan Year, the payment of an Award, if any, will be at the sole discretion of the Committee. 
 

-2- 

 

	6.	 	PERFORMANCE GOALS 

 
The Committee will establish for each Plan Year, Performance Goals designed to accomplish such financial and strategic objectives as it
may from time to time determine appropriate. The Committee may make adjustments to the Performance Goals for any Plan Year as it deems equitable in recognition of: extraordinary or nonrecurring events experienced by the Company during the Plan Year,
or changes in applicable accounting rules or principles or changes in the Company’s methods of accounting during the Plan Year. 
 

	7.	 	DETERMINATION OF AWARDS 

 
Subject to the provisions of Section 6, the Committee will determine the Awards, if any, to be made to each Participant for the Plan Year.
Awards will be based primarily on the level of performance within the performance range, but may also be based on each Participant’s contribution to overall Company performance during the Plan Year. The Award for each Participant will be
calculated by applying an Award percentage to each Participant’s salary range midpoint. 
 

	8.	 	PAYMENT OF AWARDS 

 

	 	8.1	 	Payment of Nondeferred Awards—The payment of Awards for any Plan Year will be made in cash or HEI Common Stock to the Participant as soon as practical after the
close of the Plan year unless, in the case of a cash award, the Participant irrevocably elected to defer payment of all or a portion of the Award, as provided in subparagraph 8.2 below by filing a written election form with the Company before the
beginning of the Plan Year or before the executive begins service as a Participant during the Plan Year. 

 

	 	8.2	 	Payment of Deferred Cash Awards—Each deferred Award will be credited to the Participant’s Deferred Account and will be paid to the Participant, or to his
or her beneficiary or estate in the event of his or her death, at the end of the deferral period in cash lump sum or in installments, as provided in the written election form. Amounts credited to a Participants’ Deferred account shall be
credited each year with an amount equivalent to the interest, compounded quarterly, at the annual rate commensurate with the prevailing interest rate on three-year certificates of deposit at American Savings Bank, F.S.B., as of January 1 of that
year. Such Deferred Account will be credited with interest from the date the Award would have been paid in cash to the date of receipt by the executive under the Deferral Agreement. Despite any contrary provisions in the Participant’s written
election form, the Committee, in its sole discretion, may decide to pay the balance in a Participant’s Deferred Account in a lump sum as soon as practical after the Participants’ employment by the Company is terminated for any reason.

 

-3- 

 

	 	8.3	 	In the event the payout of any portion of the awards are in HEI Common Stock, the number of shares of stock to be issued will be based on Fair Market Value.
“Fair Market Value” means, as of any determination date, the average of the daily high and low sales prices of the Common Stock on the composite tape for stocks listed on the New York Stock Exchange as quoted in the New York Stock Exchange
Composite Transactions published in the Western Edition of the Wall Street Journal on the date as of which Fair Market Value is to be determined, or if there is no trading of Common Stock on such date, the average of the daily high and low sales
prices of the Common Stock as quoted in such Composite Transactions on the next preceding date on which there was trading in such shares, or if the Common Stock is not admitted to trade on the New York Stock Exchange, the Fair Market Value shall be
determined by the Committee in such other reasonable manner as the Committee shall decide. 

 

	9.	 	ASSIGNMENTS AND TRANSFERS 

 
Participants will not assign, encumber, or transfer their rights and interests under the EICP; any attempt to do so will render the
Participants’ rights and interests under the EICP null and void. 
 

	10.	 	EMPLOYEE RIGHTS UNDER THE EICP 

 
No employee or other person will have any claim or right to be granted an Award under the EICP. Neither the EICP nor any action taken
thereunder will be construed as giving any employee any right to be retained in the employ of the Company or any of its affiliated companies. 
 

	11.	 	WITHHOLDING TAXES 

 
The Company will withhold the amount of any federal, state, or local income taxes attributable to any amounts payable under the EICP.

 

	12.	 	AMENDMENTS 

 
The Committee may amend, suspend, or terminate the EICP or any portion of it at any time. 
 

-4-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00051-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00051-of-00352.parquet"}]]